{"nctId":"NCT04074928","briefTitle":"Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects","startDateStruct":{"date":"2019-09-06","type":"ACTUAL"},"conditions":["Influenza","Human","Virus Diseases"],"count":2414,"armGroups":[{"label":"QIVc","type":"EXPERIMENTAL","interventionNames":["Biological: QIVc"]},{"label":"Comparator QIV","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator QIV"]}],"interventions":[{"name":"QIVc","otherNames":["Flucelvax Quadrivalent"]},{"name":"Comparator QIV","otherNames":["Afluria Quadrivalent"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Individuals of 6 through 47 months of age on the day of informed consent.\n* Individuals whose parent(s)/Legally Acceptable Representative (LAR) have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.\n* Individuals who can comply with study procedures including follow-up\n* Individual is in generally good health as per the Investigator's medical judgement\n\nExclusion Criteria:\n\n* Acute (severe) febrile illness\n* History of any anaphylaxis, serious vaccine reactions or hypersensitivity, including allergic reactions, to any component of vaccine or medical equipment whose use is foreseen in this study\n* A known history of Guillain-Barre Syndrome or other demyelinating diseases such as encephalomyelitis and transverse myelitis\n* Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study\n* Received influenza vaccination or has had documented influenza disease in the last 6 months prior to informed consent.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"47 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HAI) Assay Using Cell-derived Target Viruses","description":"The GMT ratio is defined as the geometric mean of the postvaccination (28 days after last vaccination) HAI titer for the Comparator QIV divided by the geometric mean of the postvaccination HAI titer for QIVc.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.0","spread":null},{"groupId":"OG001","value":"57.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","spread":null},{"groupId":"OG001","value":"26.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"19.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity Endpoint: Seroconversion Rates (SCR) and Differences in SCR Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Cell-derived Target Viruses","description":"The SCR is defined as the percentage of subjects with either a prevaccination HAI titer \\<1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a ≥4-fold increase in postvaccination HAI titer.\n\nThe SCR difference is defined as the Comparator QIV SCR minus the QIVc SCR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.24","spread":null},{"groupId":"OG001","value":"46.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.52","spread":null},{"groupId":"OG001","value":"31.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.31","spread":null},{"groupId":"OG001","value":"24.35","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity Endpoint: GMT and GMT Ratio Against the A/H3N2 Vaccine Strain by Microneutralization (MN) Assay Using Cell-derived Target Viruses","description":"The GMT ratio is defined as the geometric mean of the postvaccination (28 days after last vaccination) MN titer for the Comparator QIV divided by the geometric mean of the postvaccination MN titer for QIVc.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":null},{"groupId":"OG001","value":"23.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity Endpoint: SCR and Difference in SCR Against the A/H3N2 Vaccine Strain by MN Assay Using Cell-derived Target Viruses","description":"The SCR is defined as the percentage of subjects with either a prevaccination MN titer \\<1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a ≥4-fold increase in postvaccination MN titer.\n\nThe SCR difference is defined as the Comparator QIV SCR minus the QIVc SCR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.64","spread":null},{"groupId":"OG001","value":"30.77","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity Endpoint: GMT and GMT Ratio Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Egg-derived Target Viruses","description":"The GMT ratio is defined as the geometric mean of the postvaccination (28 days after last vaccination) HAI titer for the Comparator QIV divided by the geometric mean of the postvaccination HAI titer for QIVc.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":null},{"groupId":"OG001","value":"13.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null},{"groupId":"OG001","value":"82.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0","spread":null},{"groupId":"OG001","value":"24.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":null},{"groupId":"OG001","value":"14.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity Endpoint: SCR and Difference in SCR Against the A/H1N1, B/Victoria and B/ Yamagata Vaccine Strains by HAI Assay Using Egg-derived Target Viruses","description":"The SCR is defined as the percentage of subjects with either a prevaccination HAI titer \\<1:10 and a postvaccination HAI titer ≥1:40, or a prevaccination HAI titer ≥1:10 and a ≥4-fold increase in postvaccination HAI titer.\n\nThe SCR difference is defined as the Comparator QIV SCR minus the QIVc SCR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.52","spread":null},{"groupId":"OG001","value":"56.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.64","spread":null},{"groupId":"OG001","value":"38.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.69","spread":null},{"groupId":"OG001","value":"20.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity Endpoint: GMT and GMT Ratio Against the A/H3N2 Vaccine Strain by MN Assay Using Egg-derived Target Viruses","description":"The GMT ratio is defined as the geometric mean of the postvaccination (28 days after last vaccination) MN titer for the Comparator QIV divided by the geometric mean of the postvaccination MN titer for QIVc.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"12.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.4","spread":null},{"groupId":"OG001","value":"44.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity Endpoint: SCR and Difference in SCR Against the A/H3N2 Vaccine Strain by MN Assay Using Egg-derived Target Viruses","description":"The SCR is defined as the percentage of subjects with either a prevaccination MN titer \\<1:10 and a postvaccination MN titer ≥1:40, or a prevaccination MN titer ≥1:10 and a ≥4-fold increase in postvaccination MN titer.\n\nThe SCR difference is defined as the Comparator QIV SCR minus the QIVc SCR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.44","spread":null},{"groupId":"OG001","value":"39.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity Endpoint: Geometric Mean Ratio (GMR) Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by HAI Assay Using Cell-derived and Egg-derived Target Viruses","description":"GMR is defined as the geometric mean of the (within-subject) fold increase in serum HAI GMT postvaccination (Day 29/57) compared to prevaccination (Day 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.34","spread":null},{"groupId":"OG001","value":"3.97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.12","spread":null},{"groupId":"OG001","value":"3.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":null},{"groupId":"OG001","value":"2.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.67","spread":null},{"groupId":"OG001","value":"5.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.04","spread":null},{"groupId":"OG001","value":"3.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":null},{"groupId":"OG001","value":"2.33","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity Endpoint: GMR Against the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by MN Assay Using Cell-derived and Egg-derived Target Viruses","description":"GMR is defined as the geometric mean of the (within-subject) fold increase in serum MN GMT postvaccination (Day 29/57) compared to prevaccination (Day 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.74","spread":null},{"groupId":"OG001","value":"4.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.14","spread":null},{"groupId":"OG001","value":"2.86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.88","spread":null},{"groupId":"OG001","value":"1.63","spread":null}]}]},{"categories":[]},{"categories":[]},{"categories":[]}]},{"type":"SECONDARY","title":"Immunogenicity Endpoint: GMR Against the A/H3N2 Vaccine Strain by MN Assay Using Cell-derived and Egg-derived Target Viruses","description":"GMR is defined as the geometric mean of the (within-subject) fold increase in serum MN GMT postvaccination (Day 29/57) compared to prevaccination (Day 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.11","spread":null},{"groupId":"OG001","value":"2.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.13","spread":null},{"groupId":"OG001","value":"3.22","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Endpoint: Percentage of Subjects With Solicited Adverse Events (AEs)","description":"The percentage of subjects with at least one solicited AE Day 1 through Day 7 after any study vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"940","spread":null},{"groupId":"OG001","value":"491","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"656","spread":null},{"groupId":"OG001","value":"350","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"681","spread":null},{"groupId":"OG001","value":"358","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"240","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Endpoint: Percentage of Subjects With Any Unsolicited AEs","description":"The percentage of subjects with at least one unsolicited AE from Day 1 to Day 29 for previously vaccinated subjects and from Day 1 to Day 57 for not previously vaccinated subjects.\n\nRelated AEs = considered at least possibly related to study vaccination by the investigator; Severity = based on the greatest severity associated with a preferred term for a reported AE.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"418","spread":null},{"groupId":"OG001","value":"207","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"308","spread":null},{"groupId":"OG001","value":"164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Endpoint: Percentage of Subjects With Any Serious Adverse Events (SAEs), New Onset of Chronic Disease (NOCD) or AEs Leading to Withdrawal During the Entire Study Period","description":"The percentage of subjects with any SAE, NOCD or AE leading to withdrawal during the study period from Day 1 to Day 181 for previously vaccinated subjects or from Day 1 to Day 209 for not previously vaccinated subjects.\n\nDefinitions:\n\nSAEs = AEs defined as any untoward medical occurrence that at any dose resulted in one or more of the following: 1. Death, 2. Life-threatening 3. Required/prolonged hospitalization 4. Persistent or significant disability/incapacity 5. congenital anomaly/or birth defect 6. An important and significant medical event that may not be immediately life threatening or resulting in death or hospitalization but, based on appropriate medical judgment, may jeopardize the subject or may require intervention to prevent one of the other outcomes listed above","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":1597},"commonTop":["Injection site tenderness","Irritability","Sleepiness","Injection site erythema","Change of eating habits"]}}}